Showing results (1761-1770 of 1,947) with videos related to

Sort By:
Pageof 195
JOR Spine|August 21, 2025
Quantitative Sensory Testing in an Observational Cohort of Adults With Chronic Low Back PainMichael J Schneider, Carol M Greco, Amanda M Acevedo, et al.
Plos One|September 23, 2024
Matrix metalloproteinases mediate influenza A-associated shedding of the alveolar epithelial glycocalyxKaitlyn R Schaaf, Stuart R Landstreet, Nathan D Putz, et al.
Malaria Journal|August 13, 2024
Adapting malaria indicator surveys to investigate treatment adherence: a pilot study on Bioko Island, Equatorial GuineaDavid S Galick, Olivier Tresor Donfack, Teresa Ayingono Ondo Mifumu, et al.
The Lancet. Infectious Diseases|May 31, 2024
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trialCissy Kityo, Ivan K Mambule, Joseph Musaazi, et al.
Nature Communications|January 29, 2025
Three-dimensional diffractive acoustic tomographyLuca Menozzi, Tri Vu, Aidan J Canning, et al.
The American Journal of Medicine|November 17, 2024
Lower Risk of Death and Kidney Failure Associated with Higher Target (vs Below-Target) Doses of RAS Inhibitors in Octogenarians with HFrEFMo-Kyung Sin, Richard M Allman, Charles Faselis, et al.
BMC Microbiology|March 5, 2025
Improved protocols for isolation of Mycobacterium ulcerans from clinical samplesBernadette Agbavor, Rejoice Agyeiwaa Arthur, Abigail Agbanyo, et al.
BMC Public Health|December 14, 2018
The role of supportive supervision using mobile technology in monitoring and guiding program performance: a case study in Nigeria, 2015-2016Sisay G Tegegne, Faisal Shuaib, Fiona Braka, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical DevelopmentJeffrey M Axten, Stuart P Romeril, Arthur Shu, et al.
Nature Communications|December 31, 2024
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trialMark N Stein, Ecaterina E Dumbrava, Benjamin A Teply, et al.
Pageof 195